Report initial results from the TRuE-V Phase 3 program of ruxolitinib cream in vitiligo

Delivered by the deadline

AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.

Announced: 29 Oct 2019
Due: 31 Dec 2021

Deadline
Met
Late
Not met
Today

What the company said

“The Phase 3 TRuE-V development program of ruxolitinib cream in patients with vitiligo was initiated in September, with initial results expected in 2021.”

SourceIncyte Form 8-K press release, 2019-10-29
FilingSEC filing index
Deadline as statedin 2021
Deadline used31 Dec 2021, the last day of the stated period
TypeProduct
Permanent referenceKI-C-2019-INCY-005665
Cite as https://keptindex.org/c/KI-C-2019-INCY-005665/ — this address never changes.

What we found

Evidence strength A What the grades mean

A later 10-K states that topline Phase III TRuE-V results were announced in May 2021, before the 2021 deadline, with both studies meeting primary endpoints.

A
Incyte 10-K filed 2022-02-08 Regulatory filing · published 8 Feb 2022 · retrieved 10 Oct 2026 · kept permanently by the SEC
“In May 2021, we announced positive topline results from the Phase III TRuE-V program evaluating ruxolitinib cream as a treatment for adolescent and adult patients with vitiligo.” ✓ confirmed on the page
A
Incyte 10-Q filed 2022-05-03 Regulatory filing · published 3 May 2022 · retrieved 10 Oct 2026 · kept permanently by the SEC
“in May 2021, we announced positive topline results from the Phase III TRuE-V program evaluating ruxolitinib cream as a treatment for adolescent and adult patients with vitiligo.” ✓ confirmed on the page

Market reaction: the shares moved -9.2% against the S&P 500 over the three sessions around the disclosure (7 Feb 2022 to 10 Feb 2022). What this measures

Checked 10 Oct 2026.

Commitment lineage

Every time the company restated this commitment. The original is never changed, and the outcome is always measured against version 1.

1 versions

Version 1 · original · stated 29 Oct 2019

Deadline 31 Dec 2021 (“in 2021”) · wording expected
Version 2 · stated 9 Feb 2021

Deadline 30 Jun 2021 (“in the first half of 2021”) · wording expected

“topline results are expected to be announced in the first half of 2021”
Source for this version

Commitment DNA

The structured record of this commitment. Fields the company did not state are left blank rather than guessed.

Event type: Clinical readout late
Indicative materiality: High rules
Action: Report
Deliverable: TRuE-V Phase 3 initial results
Language: Expected (“expects”, “plans”)
In the company’s control: Medium
Specificity: Medium

How this entry was checked

Commitment recordedThe company's words were matched word for word against the filing.
First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
Second check: agreesA different AI model, Gemini (Google), re-read the evidence without being told the outcome and reached the same answer.

Confirmed. This outcome counts towards the company's Kept Score. How verification works

Are you Incyte? You can publish an official statement next to this entry, free. Add a statement.

Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.